Research programme: Dual IRAK1/4 and panFLT3 inhibitors companion diagnostics - Kurome Therapeutics
Latest Information Update: 28 May 2024
At a glance
- Originator Kurome Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Acute myeloid leukaemia
- No development reported Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Myelodysplastic-syndromes(Diagnosis) in USA
- 28 May 2024 No recent reports of development identified for research development in Solid-tumours(Diagnosis) in USA
- 29 Apr 2021 Early research in Acute myeloid leukaemia (Diagnosis) in USA